Monica R. Chmielewski

Partner

Monica R. Chmielewski

Partner

Monica R. Chmielewski is a health care and life sciences lawyer solely focused on the representation of health care providers, pharmaceutical and medical device companies, and pharmacies in health care, health care transactions, clinical research, supply chain, and food and drug law. She is a partner and vice chair of the firm’s Health Care Practice Group.

Representative Experience

Regulatory Compliance, Clinical Research, and Supply Chain

Monica provides daily counsel to numerous health systems, hospitals, academic medical centers, pharmacies and biotech, pharmaceutical and medical device companies. As such, she regularly assists clients with the following issues:

  • Regulatory compliance governing all aspects of clinical research
  • Investigations of research misconduct
  • Institutional Review Board (IRB) issues
  • The conduct of U.S. and international clinical trials
  • Research grants and funding
  • Government investigations and audits
  • Pharmaceutical product promotion (including counsel on off-label promotion)
  • 510K applications
  • The regulation of software as a medical device
  • Mobile medical applications
  • Continuing Medical Education (CME)
  • Preparation of research contracts
  • Grant contracts and administration
  • Pharmacy Benefit Managers (PBM) matters
  • Good clinical practice (GCP) issues
  • Customs import and export issues
  • Hospital and physician issues
  • Supply chain matters (including formation of and contracting with group purchasing organizations)
  • Corporate practice of medicine and dentistry prohibitions
  • Joint venture and other collaborative efforts
  • Preparation and review of hospital
  • Physician and other provider contracts
  • Accountable care organization (ACO) formation and operation
  • HIPAA
  • Physician recruitment
  • Corporate compliance issues
  • Medical staff and peer review
  • Accreditation matters
  • Supply chain and procurement issues

She also has participated as transactional counsel in numerous health care, life science, and corporate transactions, including the merger, purchase and sale, or transfer of sponsorship of hospitals, pharmacies, contract research organizations (CROs), physician-owned surgery centers, health systems, home health agencies, hospices and physician practices; and the formation of ancillary services joint ventures; and counsels investors (venture capital and private equity) in investments, acquisitions, and sales.

Monica has in-depth knowledge of federal and state regulation of the drug and device supply chain, pharmacies, and laboratories. She advises entities (industry), health care providers, investors, and lenders on transactional matters and regulatory compliance, including mergers and acquisitions, recapitalizations, buyouts, restructurings, joint ventures, and broad range of commercial transactions.

Monica provides daily counsel on supply chain and materials management issues, and counsels on group purchasing organization (GPO) negotiations and formation. She also counsels health plans in their procurement of and contracting with PBMs for mail, retail, and specialty drug services in connection with commercial and government health care programs. In addition, she provides counsel regarding PBM audits, as well as on regulatory issues for various retail and specialty pharmacies, including state Boards of Pharmacy inspection and adverse findings, compounding pharmacy matters, and licensure among others.

Compliance

Monica counsels health care entities, pharmaceutical and medical device companies, pharmacies and laboratories regarding the operation and functions of their corporate compliance and integrity programs, including assisting with the composition and development of programs; reviewing and assessing existing program effectiveness; providing compliance education and training of personnel, executive management and board members; coordinating internal investigations of compliance related concerns; and recommending any needed corrective action. She has counseled, in both in-house and outside counsel roles, individual hospitals, health systems, hospices, skilled nursing facilities, and pharmaceutical companies on matters of corporate compliance.

Telemedicine

“Foley is the premier firm for telehealth counsel.”
“A market leader in telemedicine issues.” “This is the Dream Team.”
– Chambers USA: America’s Leading Business Lawyers (2020, 2021)

Monica advises a number of clients, including hospitals, health systems and physician groups on regulatory and compliance issues presented by telemedicine and telehealth. Her counsel includes, but is not limited to, structuring, and negotiating professional services agreements for telemedicine services and composing telemedicine policies and procures.

Fraud and Abuse, False Claim Act, and Health Care Fraud Investigations

Monica’s experience includes particular compliance issues arising under the False Claims Act (FCA), Stark Law, Anti-Kickback Statute, EMTALA, Civil Monetary Penalties Law, licensure/certification, and HIPAA. Monica works with providers on properly responding to governmental and accreditation audits and more formal investigations as well as directly with provider compliance officers and general counsel to advise them on the latest legal and Office of Inspector General requirements and standards.

Awards and Recognition

  • Chambers USA: America’s Leading Business Lawyers, Healthcare: Pharmaceutical/Medical Products Regulatory (2020-2024)
  • The Legal 500, Life Sciences (2014)
  • Named a Thomson Reuters Stand-out Lawyer (2023-2024)

Presentations and Publications

  • Co-author, “FDA Clinical Investigations: New Guidance on Electronic Systems,” Health Care Law Today (November 20, 2024)
  • Co-author, “Cancer Drugs: Clinical Trial Issues for Antibody Drug Conjugates (ADCs)/Antibody Therapeutics,” Health Care Law Today (November 5, 2024)
  • Speaker, “Medical Research Misconduct Proceedings: New HHS-ORI Final Rule; Key Procedural Reforms and Requirements,“ Strafford Webinar (December 4, 2024)
  • Co-author, “Decentralized Clinical Trials: Research Misconduct Risks & How to Avoid Them,” Health Care Law Today (September 30, 2024)
  • Speaker, “Examine the Recent FDA Guidance Surrounding Digital Health Technologies,“ 5th Clinical Trial Agreements (August 22, 2024)
  • Co-author, “Clinical Trials: FDA Publishes Draft Guidance on Diversity Action Plans,” Health Care Law Today (July 25, 2024)
20 November 2024 Health Care Law Today

FDA Clinical Investigations: New Guidance on Electronic Systems

On October 2, 2024, the FDA released guidance in a question and answer format regarding the use of electronic systems, electronic records, and electronic signatures in clinical investigations of medical products, foods, tobacco products, and new animal drugs.
12 November 2024 Innovative Technology Insights

Key Takeaways From TEDAI 2024

Our team examines the overarching themes in focus at TEDAI 2024.
05 November 2024 Health Care Law Today

Cancer Drugs: Clinical Trial Issues for Antibody Drug Conjugates (ADCs)/Antibody Therapeutics

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs and an antibody conjugated together by a chemical linker.
04 December 2024 Events

Medical Research Misconduct Proceedings: New HHS-ORI Final Rule; Key Procedural Reforms and Requirements

Foley partner Monica Chmielewski, vice chair of the firm’s Health Care Practice Group, is speaking in the upcoming Strafford webinar "Medical Research Misconduct Proceedings: New HHS-ORI Final Rule; Key Procedural Reforms and Requirements" on December 4.
23 October 2024 Events

TED AI 2024

Foley & Lardner has once again teamed up with TED AI for the 2024 edition of San Francisco's premier artificial intelligence gathering, and we're inviting you to join us for a full day of exciting programming at the Ferry Building.
30 September 2024 Health Care Law Today

Decentralized Clinical Trials: Research Misconduct Risks & How to Avoid Them

The COVID-19 Pandemic required the health care industry to adapt to accommodate remote patient care, including for patients involved in clinical trials, and the use of Decentralized Clinical Trials proliferated during the Pandemic.